GLP-1 Coverage by Insurance Plan

Find out exactly what your insurance plan covers for Wegovy, Ozempic, Zepbound, and Mounjaro in 2026.

Editorial note: Insurance coverage of GLP-1 medications is changing rapidly as plans respond to new clinical evidence and shifting federal and state policy. Always verify current coverage rules with your own plan administrator or member services line before making a treatment or financial decision based on any information on this page.
Blue Cross Blue Shield
119,100,000 members · Coverage: varies
Medicaid
90,000,000 members · Coverage: varies
Medicare
67,000,000 members · Coverage: limited
UnitedHealthcare
49,800,000 members · Coverage: varies
Anthem
47,000,000 members · Coverage: varies
Aetna
39,000,000 members · Coverage: varies
Cigna
18,000,000 members · Coverage: varies
Humana
17,000,000 members · Coverage: limited
Kaiser Permanente
12,700,000 members · Coverage: limited
TRICARE (Military)
9,600,000 members · Coverage: limited
Coverage hub

Find your state Medicaid coverage →

Verbatim primary-source coverage analyses for 11+ state Medicaid programs (and growing) — PDLs, provider notices, federal statute, and state regulation. Pattern groups, 50-state grid, and a comprehensive table.

→

Most editorially distinctive state cases

A handful of states show the most structurally unique coverage patterns. Reading these first is the fastest way to understand how state Medicaid GLP-1 coverage actually works in 2026.

North Carolina — positive coverage
Double reversal: terminated October 2025 then reinstated December 2025 within 73 days. The first state with Wegovy listed as Preferred for chronic weight management.
Pennsylvania — policy reversal
Inverse of California: PA TERMINATED GLP-1 obesity coverage on Jan 1, 2026 after 34 months. Triple-anchored on MAB2025112403 + 55 Pa.B. 8828 + 55 Pa. Code § 1121.54. $836M/year FY26-27 savings rationale.
California — reversed course
Wegovy + Zepbound for weight loss removed January 1, 2026; Wegovy re-added April 1, 2026 for MASH only with ICD-10 K76.0 / K75.8 (not for chronic weight management).
New York — strongest-evidenced
Triple-anchored on federal 42 USC + state regulation 18 NYCRR § 505.3(g)(3) + NYRx contractor brand-named exclusion. Narrow Wegovy MACE pathway with NY-specific BMI ≥ 40 + 2-attempt cap.
Florida — silent operational exclusion
Operational by absence in the AHCA PDL plus verbatim plan-level deferrals from Sunshine, Humana, Simply, Molina, and Aetna BH FL.
Tennessee — positive-coverage expansion
TennCare ADDED obesity-indication coverage Aug 1, 2025 via Sequence 10-34-25 rulemaking. Broadest AOM panel + 5-indication GLP-1 PA form (T2D + obesity + MACE + OSA + MASH).

Looking for a different state? See the full state-by-state coverage hub →

Sources & methodology — as of May 2026
  1. 1.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  2. 2.CMS — Medicare Part D Prescription Drug Coverage Program— Centers for Medicare & Medicaid Services.
  3. 3.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.